ROCHESTER, Minn. — Mayo Clinic Platform_Accelerate has announced its latest cohort, welcoming 18 national and international healthcare technology companies that are creating cutting-edge digital solutions to advance health innovation.

Through the Accelerate program, these companies will participate in an immersive, 30-week program that offers access to expert mentors, industry-leading technologies and millions of de-identified, longitudinal clinical records to develop and validate artificial intelligence (AI)-driven healthcare solutions.

"The future of healthcare depends on clinical insight and technology advancing together," says John Halamka, M.D., Dwight and Dian Diercks President of Mayo Clinic Platform. "Accelerate brings entrepreneurs together with Mayo Clinic clinicians and other leading experts to turn bold ideas into practical solutions that can truly improve how care is delivered. It's one more way we're responsibly advancing AI to benefit patients around the world."

The 18 companies participating in the new cohort are working to address complex healthcare challenges. The cohort includes:

• 100ms builds AI agents that automate patient access workflows for specialty practices, including gastroenterology, allergy/immunology and neurology.
• NousLogic Telehealth provides WFH: Wellness from Home, a remote elderly patient monitoring platform that tracks vital signs and real-time medication adherence, including AI-based medication dispensing. 
• MyBackHub is an AI-powered digital health platform that delivers personalized, nonoperative back pain care using AI to triage patients and guide treatment and care coordination.
• Cura AI builds a patient context graph that unifies fragmented patient data into a portable, patient-owned record, enabling conversational AI to support early-risk detection and preventive care.
• SPRYT developsAsa, an AI medical receptionist that empowers patients to book, change and pay for medical appointments via text or instant messaging in their preferred language.
• NeoCure Inc. is developing an AI solution that analyzes bedside vital data to enable timely, specialist-free detection of an eye disease affecting preterm infants.
• Xcoo provides Chrovis, an AI-powered service that supports genomic cancer diagnosis and treatment decisions with clinician-ready insights and patient-friendly reports.
• YOBO Health offers a care coordination platform designed to help prevent hospital readmissions among patients with cardio-renal-metabolic conditions.
• Canary Applied Intelligence delivers a patient-centric AI platform for cardio-renal care that identifies high-risk patients early and enables proactive, data-driven interventions across the care journey.
• Curenetics is a U.K.-based AI-driven health technology company that predicts individual patient response to cancer immunotherapy by integrating clinical, genomic and imaging data.
• Bluevia Health is an applied AI platform that analyzes multimodal clinical data to detect postoperative deterioration earlier, helping health systems identify complications sooner and improve surgical outcomes.
• Precision Imaging Inc. is a Tokyo-based medtech startup specializing in AI-powered intraoperative navigation that uses computer vision to deliver cost-effective, high-precision guidance for orthopedic surgery, starting with total hip arthroplasty.
• Avedian provides the Compass Decision Support platform, delivering operational insights that help health systems improve efficiency, performance and capacity planning.
• Hoopcare reduces surgical risk and improves operating room efficiency by automating preoperative evaluation and predicting postoperative complications with AI.
• Hera is an AI-powered male fertility platform that combines testing with predictive analytics to deliver personalized sperm health insights for patients, clinics and fertility programs.
• EW2Health is a digital health platform that uses predictive behavioral analytics to support GLP-1–based obesity care by forecasting weight trends and enabling proactive, personalized interventions to improve adherence and long-term metabolic health.
• Ecotone AI applies frontier AI and full-genome analysis to uncover disease-driving genetic mechanisms and accelerate precision therapies for rare diseases at scale.
• OneMedic is a Vietnam-based health tech company using an AI-driven ecosystem to enable early detection and proactive management of chronic disease through integrated, patient-centered care in a primary care setting.

"The innovation we're seeing in this February cohort is a testament to the accelerating pace of AI in medicine," says Jamie Sundsbak, director of the Accelerate program. "We are proud to support these 18 companies as they transition from revolutionary concepts to scalable solutions that can help define the next decade of healthcare."

The Accelerate program offers multiple ways to participate through a 30-week immersive program or a multiyear engagement pathway.

To learn more about the program or to apply for an upcoming cohort, visit Mayo Clinic Platform_Accelerate.

###

About Mayo Clinic Platform  
Founded on Mayo Clinic's dedication to patient-centered care, Mayo Clinic Platform enables new knowledge, new solutions and new technologies through collaborations with health technology innovators to create a healthier world. To learn more, visit Mayo Clinic Platform. 

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

Media contact:

• Caroline Auger, Mayo Clinic Communications, newsbureau@mayo.edu

The post Mayo Clinic Platform_Accelerate welcomes new cohort of healthcare technology startups appeared first on Mayo Clinic News Network.

ROCHESTER, Minn. — In 2025, Mayo Clinic advanced cures, accelerated diagnoses and expanded access to care through its Bold. Forward. strategy, introducing hundreds of innovations to better serve patients worldwide.

"Guided by our primary value of putting the needs of our patients first, 2025 was another strong year for Mayo Clinic," said Gianrico Farrugia, M.D., president and CEO. "Through our Bold. Forward. strategy, we delivered new capabilities that meaningfully improved patients’ lives and positioned us to accelerate patient-centered transformation in the year ahead."

Digital innovation and Mayo Clinic Platform

Data-powered innovations and strategic collaborations helped identify diagnoses earlier and enabled new therapies to reach patients faster. In 2025, Mayo Clinic integrated 22 Mayo Clinic Platform-driven solutions into clinical practice, enhancing AI-enabled care and streamlining workflows. For example, the PSA Control Tower supports earlier detection of prostate cancer recurrence. Also, researchers can now analyze data from thousands of glioblastoma patients in minutes rather than years.

At the same time, Mayo Clinic Platform expanded its global reach through Mayo Clinic Platform_Orchestrate, which helps biopharma and medical device companies accelerate clinical development to get patients therapies faster, and Mayo Clinic Platform_Insights, which gives healthcare organizations worldwide access to Mayo Clinic expertise and data-driven insights to overcome barriers to the responsible implementation of AI solutions.

Innovation is strongest when shaped by those closest to patients. In 2025, a multidisciplinary team led by the Department of Nursing at Mayo Clinic developed the AI-powered Nurse Virtual Assistant, created by nurses for nurses. This solution delivers patient summaries and direct links to evidence-based resources, giving nurses more time to focus on care.

These digital advances also contributed to expanded access and new collaborations. Outpatient digital visits increased 17% to 1.2 million compared to 2024. Additionally, nearly 300 technologies were licensed, and close to 200 new agreements were signed across biopharma, diagnostics and AI, expanding access to Mayo Clinic knowledge worldwide.

Accelerating research and discovery

Clinical trial activity increased 20% over 2024, with activation times cut in half for one-third of studies. Virtual trial models expanded participation and accelerated results, allowing promising therapies to reach patients faster. Researchers also advanced work in heart failure, kidney disease, Alzheimer’s disease and breast cancer, using data-driven tools to predict, prevent and treat complex diseases earlier and more precisely.

Excellence in patient care

These advances translated directly into care delivery. Mayo Clinic cared for patients from every state and more than 140 countries, including 161,590 surgical patients, an increase of more than 4% from 2024. Additionally, Mayo Clinic performed 2,065 solid-organ transplants, the most in the nation. Teams introduced 149 new surgeries and procedures and delivered more than 26 million diagnostic tests, including 100 new tests.

This commitment to excellence continued to earn national and global recognition. In 2025, Mayo Clinic was named World’s Best Hospital for the seventh consecutive year and World’s Best Smart Hospital by Newsweek. U.S. News & World Report ranked Mayo Clinic in the top three in more specialties than any other hospital for 36 straight years.

Workforce expansion

Behind this progress was continued growth in Mayo Clinic’s workforce. The organization welcomed more than 12,400 new colleagues in 2025, bringing total staff to nearly 85,000, and educated more than 5,000 students and trainees across the Mayo Clinic College of Medicine and Science.

"The work of Mayo Clinic begins and ends with our people," said Christina Zorn, chief administrative officer. "Across every role and every campus, our staff bring extraordinary skill, compassion and teamwork to patients each day. Their commitment to one another and to those we serve is what turns our strategy into action and makes our mission possible."

Building the future of healthcare: Bold. Forward. Unbound.

Investment in the future of care continued through Bold. Forward. Unbound., the $9 billion investment integrating advanced digital capabilities with modern clinical environments. Construction progressed in Rochester, including expanded proton beam therapy capacity. In Arizona, Mayo Clinic announced a major transformation of its Phoenix campus. In Florida, a new five-floor patient tower added 166 beds, and the Duan Family Building opened, bringing advanced photon and proton therapy, and the first carbon ion therapy program being built in the Americas. Mayo Clinic Health System also broke ground on a new hospital in Sparta, Wisconsin, strengthening care in rural communities.

Reflecting strong confidence in Mayo Clinic’s mission and impact, philanthropic support reached $1.47 billion in 2025, and Mayo Clinic generated $473 million in operating income, a 2.3% margin.

"Mayo Clinic exists for one reason only, to help patients," said Dr. Farrugia. "In 2025, we were able to help more people in new ways than ever before, and we will continue striving to bring even more hope and healing in 2026."

The post Mayo Clinic’s 2025 performance advances its patient-centered mission appeared first on Mayo Clinic News Network.

Newsweek named Mayo Clinic the No. 1 hospital in its annual list of the "World's Best Hospitals" for the eighth consecutive year. The rankings were released on Wednesday, Feb. 25.

Newsweek has named Mayo Clinic the No. 1 hospital in the world for the eighth straight year in its 2026 World’s Best Hospitals list.  

"This recognition is a result of the extraordinary expertise, compassion and commitment of our staff, all working together to transform healthcare and find more cures for the benefit of people everywhere," says Gianrico Farrugia, M.D., president and CEO of Mayo Clinic. "Over the past year, we accelerated that transformation by responsibly integrating data, technology and AI into patient care."

The annual Newsweek rankings are based on patient survey results; an international survey of more than 85,000 healthcare professionals; key performance metrics, such as patient safety and quality of care; and implementation of patient-reported outcomes.

Through its Bold. Forward. strategy, Mayo Clinic is reimagining healthcare to ensure patients everywhere receive better answers and better outcomes. By combining deep clinical expertise with responsible digital innovation, the organization is transforming how care is delivered. Central to this effort is Mayo Clinic Platform, which drives the development, validation and deployment of AI in real-world clinical settings with partners across four continents.

See the full "World's Best Hospitals" list.

The post Eight years running: Newsweek names Mayo Clinic ‘World’s Best Hospital’ appeared first on Mayo Clinic News Network.

This episode of "Tomorrow's Cure" explores the dramatic changes happening in pediatric care thanks to whole genome sequencing. Hear from Whitney Thompson, M.D., assistant professor of medical genetics and pediatrics at Mayo Clinic, Stephen Kingsmore, M.D. president and CEO of Rady Children's Institute for Genomic Medicine, and Sean George, CEO of Inflection Medicine, as they discuss the life-changing feeling of identifying rare genetic diseases and giving patients a precise diagnosis. 

In the recent past, a step-by-step approach once meant going through one genetic test and getting no answer, then another. This model was how testing started. Dr. Thompson explains the significant changes in practice in the neonatal intensive care unit (NICU) in the last five years. 

"We send what we call "rapid whole genome sequencing," one comprehensive rapid test that can look at ... all the genes that we know currently to cause disease and hopefully find an answer for families," she says. 

The Human Genome project has helped change the standard of care. Dr. Thompson says questioning if there's a genetic disease at play becomes the first lens of treatment, a new paradigm in the NICU. With this mindset, physicians can order a rapid genome test to get instant answers. 

This episode also explores how AI has helped researchers continue to read and understand the genomic map. As researchers find success in genomic treatments and testing, the next step is finding ways to scale these solutions. Currently, cases are treated on an individual basis as custom therapies are developed. 

The trio also discusses how these projects aren't restricted to babies. All humans have their genome throughout their entire lives, and new insights can appear at every stage of life. As teams begin to prove the cost-effectiveness of a rapid genome test over other "diagnostic odysseys," policy is starting to follow. The team discusses how California and other states are applying this paradigm to Medicaid patients because not only do physicians get a result so much faster, but the process is more cost-effective. 

The researchers talk with host Cathy Wurzer about where genomic testing and treatments are headed and what it will take to achieve these insights at scale.

Listen to the latest episode of "Tomorrow's Cure" wherever you get your podcasts. You can explore the full library of episodes and guests on the show's page.  

The post Tomorrow’s Cure: Shortening the diagnostic journey appeared first on Mayo Clinic News Network.

ROCHESTER, Minn. — Mayo Clinic announced today that researchers and solutions developers now have access to decades of high-level, de-identified data from Mercy through Mayo Clinic Platform's secure, privacy-preserving infrastructure. Mercy, one of the 15 largest health systems in the U.S., has 55 acute care and specialty hospitals in both urban and rural communities in the Midwest.

Through Mayo Clinic Platform, researchers, data scientists and innovators can now analyze larger, more diverse patient populations from both Mayo Clinic and Mercy to explore new ways to diagnose, treat and prevent diseases. This expanded data set enhances research by reducing demographic bias that can occur with single-institution data, and it supports more representative research studies.

With this data collaboration, Mayo Clinic Platform now provides visibility into de-identified data from more than 15.2 million patients, including:

• 12.6 billion images
• 3.2 billion lab test results
• 10.1 million pathology reports
• 1.65 billion clinical notes

"This collaboration opens the door to insights no single health system could achieve alone and reflects Mayo Clinic's commitment to transforming the future of healthcare," says John Halamka, M.D., Dwight and Dian Diercks President, Mayo Clinic Platform. "This work is designed to drive innovation in healthcare by accelerating research and enabling the creation of new solutions that transform future clinical practice."

Using Mayo Clinic Platform's secure capabilities, each organization retains full control of its own information. No data is transferred or moved.

"This joint effort will transform healthcare to predict illness earlier, improve outcomes, shorten hospital stays, and deliver more proactive, patient-centered care that ultimately saves lives," says Gavin Helton, M.D., Mercy's president of primary care.

This collaboration is part of a 10-year agreement between Mercy and Mayo Clinic to transform healthcare. By adding insights from more diverse patient populations, the two organizations have taken a significant step forward in accelerating research and supporting future advances in patient care.

Mercy is a founding member of Mayo Clinic Platform_Connect, a first-of-its-kind global health data network that links healthcare innovators and provides access to clean, curated and de-identified data sets—enabling richer insights, faster decisions and more equitable patient care.

Through Connect, Mayo Clinic is also collaborating with other leading healthcare organizations worldwide. Access to additional de-identified patient data from these healthcare organizations is expected to become available through Mayo Clinic Platform later this year.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

About Mayo Clinic Platform
Founded on Mayo Clinic's dedication to patient-centered care, Mayo Clinic Platform enables new knowledge, new solutions and new technologies through collaborations with health technology innovators to create a healthier world. To learn more, visit Mayo Clinic Platform.

About Mercy
Mercy, one of the 15 largest U.S. health systems and named the top large system in the U.S. for excellent patient experience by NRC Health, serves millions annually with nationally recognized care and one of the nation's largest and highest performing Accountable Care Organizations in quality and cost. Mercy is a highly integrated, multistate healthcare system including 55 acute care and specialty (heart, children's, orthopedic and rehab) hospitals, convenient and urgent care locations, imaging centers and pharmacies. Mercy has over 1,000 physician practice locations and outpatient facilities, more than 5,000 physicians and advanced practitioners, and more than 50,000 caregivers serving patients and families across Arkansas, Illinois, Kansas, Missouri and Oklahoma. Mercy also has clinics, outpatient services and outreach ministries in Arkansas, Louisiana, Mississippi and Texas. In fiscal year 2025 alone, Mercy provided more than half a billion dollars of free care and other community benefits, including traditional charity care and unreimbursed Medicaid.

Media contacts:

• Caroline Auger, Mayo Clinic Platform Communications, newsbureau@mayo.edu
• Nancy Dixon, Mercy Communications, nancy.dixon@mercy.net

The post Mayo Clinic and Mercy advance collaboration to transform patient care appeared first on Mayo Clinic News Network.

Strategic collaboration brings together Mayo Clinic's extensive clinical insights, genomic data and Platform architecture with Merck's artificial intelligence (AI) and machine learning (ML) research capabilities

RAHWAY, N.J., and ROCHESTER, Minn. — Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, and Mayo Clinic, the world's top-ranked hospital system, today announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data to support drug discovery and development. The agreement integrates Mayo Clinic's Platform architecture as well as clinical and genomic datasets with Merck's ambition to harness AI-enabled virtual cell technologies to enhance disease understanding, improve target identification, and drive early development decisions.

By leveraging Mayo Clinic Platform, which brings together data from Mayo Clinic U.S. and its international partner network in a secure environment, Merck will integrate Mayo Clinic's clinical insights and genomic data sets, including AI and machine learning (ML)-enabled discovery spanning computational and spatial biology. The new Mayo Clinic Platform_Orchestrate program provides Merck direct access to Mayo Clinic's world-class clinical and scientific expertise, Platform data including de-identified clinical and multimodal data sets, registries and biorepositories, advanced AI tools and analytics, and the ability to scale solutions.

Under the agreement, which marks Mayo Clinic's first strategic collaboration of this scale with a global biopharmaceutical company, Merck will leverage Mayo Clinic's extensive multimodal data — including laboratory results, medical imaging, clinical notes and molecular data — to support validation of AI models and help translate research insights into discovery and development strategies.

“New cutting-edge technologies are enhancing our ability to innovate with the potential to bring important new therapies to patients faster. By working with Mayo Clinic, we aim to integrate high-quality clinical data and AI-enabled insights into discovery research to improve target identification, and ultimately, the probability of success for our programs," said Robert M. Davis, chairman and CEO, Merck.

“By combining Mayo Clinic Platform's de-identified data, clinical expertise and Platform technology with Merck's world-class research and development capabilities, we are poised to speed innovative breakthroughs to patients and redefine drug development," said Gianrico Farrugia, M.D., president and CEO, Mayo Clinic. "This collaboration represents a new present and future for healthcare — one where platform-based collaboration leads to more answers, more cures and better outcomes for patients worldwide."

The collaboration will initially focus on high-need therapeutic areas in three specialties where advanced analytics and multimodal approaches have the potential to advance progress in the development of more effective and tailored therapies:

• Gastroenterology — Inflammatory Bowel Disease (IBD)
• Dermatology — Atopic dermatitis
• Neurology — Multiple sclerosis

The collaboration builds on Merck's broader investments in AI/ML-enabled discovery, spanning computational or spatial biology, AI foundation models and real-world data, and reflects a shared focus on applying advanced technologies in ways that support disciplined, evidence-based drug development.

###

About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world — and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

About Mayo Clinic  
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. 

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Media contacts:

• Dan Pierce, Mayo Clinic Communications, newsbureau@mayo.edu
• Eilyn Segura, Merck, 203-940-6259
• Toneisha Friday Smith, Merck, 609-455-6000

Investor contacts:

• Peter Dannenbaum, 732-594-1579
• Steven Graziano, 732-594-1583

The post Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine appeared first on Mayo Clinic News Network.

This episode  of "Tomorrow's Cure" explores how AI and automation can be harnessed for healthcare. We hear from Ravi Bapna, Ph.D., the Curtis L. Carlson Chair Professor in Business Analytics and Information Systems at the Carlson School of Management at the University of Minnesota, and Anjali Bhagra, M.D., a clinical investigative internist at Mayo Clinic, as they discuss how we are adding these tools to our toolbox to help create scalable solutions to age-old problems. 

AI is integrated into much of healthcare, and that integration prioritizes how researchers enable more focus on the patient. Tools like ambient AI for recording patient conversations help free up administrative time to physicians and ultimately patients. "I give my full attention to my patients when I'm in the room with them, without being distracted. I think that ... has allowed me to be more human, more present, more in tune with patients' emotions," says Dr. Bhagra. 

The episode also dives into the buckets of traditional AI and predictive AI. Complex care often brings with it consults from many physicians and vast medical records. AI can accumulate and analyze all that data in comparison to similar records, helping to map trends or new opportunities for understanding. 

The guests agree there is much more to learn. "We are still harnessing only a very, very small fraction of the data we generate as a society," Bapna says. 

For both researchers, the human being remains centered in this conversation and much of their work is focused on freeing up scarce resources, which in this case is physicians' time. From there, the core questions teams are approaching are how to augment human capacity and knowledge. That also calls for an understanding of automation and how to align people and processes. 

The researchers talk with host Cathy Wurzer about society's adaptation to digital life and how innovations such as patient records and test results are now available through new technologies like apps. They discuss how this access to information can help patients be proactive and lead to better communication with their physician. 

Listen to the latest episode of "Tomorrow's Cure" wherever you get your podcasts. You can explore the full library of episodes and guests on the show's page.  

The post Tomorrow’s Cure: The future of patient-centered AI   appeared first on Mayo Clinic News Network.

When Karen Koellner reached for her phone charger while in bed one night, she felt pain. Curious, she got up and went to her bathroom mirror to check — and her instinct told her something was definitely wrong. She found a lump in her armpit and knew it might be cancer.

The next day, she called her doctor, who referred her to Mayo Clinic's Arizona campus. Fear set in as she expected to wait days before getting an appointment.

Instead, she received a call within two hours.

Manual processes and paperwork are often part of healthcare, but these tasks can take valuable time away from patient care. They can also delay care for patients who need it most.

That is beginning to change.

Intelligent automation helps Mayo Clinic move faster and smarter. A new automation initiative is already improving the experience for patients like Karen, who was diagnosed with stage 3 breast cancer. An intelligent referral processing system flagged her case as urgent based on clinical patterns, prompting staff to reach out right away. Her appointments were scheduled across multiple specialties the next day, with care teams coordinating across states, disciplines and workflows.

"Being seen by an oncologist quickly was important to me," Karen says. "I was able to move forward with a treatment plan rather than waiting and worrying about the unknown."

The automated document referral system was developed at Mayo Clinic to triage incoming patient referrals using generative artificial intelligence (AI) in place of faxes, which had to be processed by hand. By eliminating one of the most time-consuming administrative workflows, the system shortens referral timelines and strengthens coordination across care teams. That means staff can spend more time focused on patients — and anxious patients like Karen experience less of a wait during the critical time between diagnosis and their first appointment.

"That is a crucial time period for patients with serious and complex medical conditions, when every moment truly matters," says Erin Layman, operations manager for Hematology and Medical Oncology at Mayo Clinic in Arizona. "It's important to have an intelligent system that can pull information from multiple documents, summarize it and allow staff to quickly review for accuracy. That helps move high-risk patients through the process much faster."

Karen calls it a game-changer in healthcare.

"Automation for patients with time-sensitive, critical diseases such as cancer has the potential to save lives by getting treatment plans started as soon as possible," she says.

The system, used in multiple departments across Mayo Clinic, worked to Karen’s advantage. Now finished with her treatment, she says she's feeling much better and is grateful to be cancer-free.

The post From fear to a phone call in 2 hours, breast cancer patient gets care faster with the help of intelligent automation appeared first on Mayo Clinic News Network.

Join healthcare innovators for Mayo Clinic's annual AI Research Summit on June 4–5 in Rochester, Minnesota. This premier conference brings together leading experts to explore advances in artificial intelligence (AI) in healthcare, share emerging methods and best practices, and discover new collaborations. A virtual attendance option is also available.

This year's summit will highlight multi-agent modeling and simulation as a new approach for generating real-world evidence. 

"At Mayo Clinic, we are leading the development of AI methods — such as multi‑agent systems and simulation — that allow us to model complex patient scenarios and generate rigorous evidence far faster than traditional approaches," says Dr. Cui Tao, the Nancy Peretsman and Robert Scully Chair of Artificial Intelligence and Informatics at Mayo Clinic.

"These tools are helping us compress what once took years of trials and discovery into months, enabling trustworthy AI solutions that support better decisions and accelerate cures. This year's summit brings together researchers, data scientists, students and clinicians to drive this progress, and we are pleased to partner with our colleagues who help move scientific advances into practice," Dr. Tao says. 

The program will explore topics such as multi-agent clinical intelligence, simulation, virtual twins and multimodal foundation models. Sessions will also focus on translating AI research into clinical practice and building trustworthy, governable systems.

The event's keynote speakers are: 

• Cui Tao, Ph.D., the Nancy Peretsman and Robert Scully Chair of Artificial Intelligence and Informatics at Mayo Clinic
• Yong Chen, Ph.D., director of the Center for Health AI and Synthesis of Evidence at the Perelman School of Medicine, University of Pennsylvania
• Peter Lee, Ph.D., president of Microsoft Research and Mayo Clinic Trustee
• Micky Tripathi, Ph.D., chief AI implementation officer at Mayo Clinic
• Yi Qian, vice president of Global Real-World Evidence at Johnson & Johnson 
• Matt Redlon, senior administrator, AI Program at Mayo Clinic

Early-bird registration is available through April 30 on the event website.

Submit your work for presentation

Present your work to an audience that includes experts from Mayo Clinic, industry and top academic institutions. Proposals are being accepted for three presentation formats: 

• 10-minute lightning talks
• Poster presentations
• Workshops and tutorials

Abstracts selected for top recognition will be published in Mayo Clinic Proceedings: Digital Health. A subset of presenters will be invited to expand their work into full articles for publication after peer review. 

Proposals may be submitted through the AI Research Summit website as part of the event registration process. Abstract submissions will be accepted through March 6.

Learn more

Learn more and register on the event website.

The post Connect with leading experts at Mayo Clinic’s AI Research Summit appeared first on Mayo Clinic News Network.

ROCHESTER, Minn. — Mayo Clinic announced today additional capabilities within Mayo Clinic Platform_Orchestrate that make it more efficient for researchers to access standardized, real-world cancer data from Mayo Clinic and participating Mayo Clinic Platform_Connect partners. This gives researchers the ability to generate insights that can accelerate cancer research and improve patient care.

Developing new cancer therapies is a long and complex process that typically takes many years. Orchestrate's capabilities can help shorten this timeline by giving researchers faster access to high-quality, real-world cancer data.

Orchestrate is now using an industry-leading, standardized framework to organize complex cancer information, known as Observational Medical Outcomes Partnership (OMOP) Oncology. The new function can present de-identified data in a consistent, structured and research-ready format. This includes standardized information such as tumor characteristics, biomarkers, staging, treatments, progression and outcomes. These key oncology attributes are refined from a rich background of structured data (e.g., diagnoses, lab test results) and unstructured data (e.g., imaging, pathology and radiology reports) already integrated on Mayo Clinic Platform to enable better clinical insights and research.

The OMOP Oncology model is a product of the global Observational Health Data Sciences and Informatics (OHDSI) initiative. The model's standardized structureallows researchers to analyze complex cancer data more rapidly, accurately and on a larger scale than before.

"The integration of OMOP Oncology into Mayo Clinic Platform has the power to accelerate discovery, improve clinical trial design, unlock real-world insights and support the development of next-generation therapies for patients worldwide," said Elisabeth Heath, M.D., chair of the Department of Oncology at Mayo Clinic.

Nemesis Health, a research and technology service provider for Mayo Clinic Platform, contributed to the development of OMOP Oncology capabilities on Orchestrate.

This year, Mayo Clinic Platform will also incorporate tokenization, a technology that connects de-identified information from across a patient's care experience to provide a more complete, longitudinal view of their healthcare journey. Combined with the OMOP Oncology model, this will give researchers a more comprehensive understanding of a patient's cancer care pathway before, during and after their care at Mayo Clinic.

Launched in 2025, Orchestrate builds on Mayo Clinic Platform's trusted data ecosystem that offers a secure and reliable environment for research and innovation. With these enhanced capabilities, researchers and others seeking to solve healthcare challenges can more easily identify and analyze key groups of people who share common characteristics, understand treatment and outcome patterns, assess the feasibility of clinical trials, and generate real-world evidence to support the development of new cancer therapies.

"Orchestrate strengthens Mayo Clinic's commitment to advancing cancer care through data-driven innovation," says Maneesh Goyal, chief operating officer, Mayo Clinic Platform. "By combining trusted data, advanced artificial intelligence and Mayo Clinic’s scientific expertise, these capabilities help unlock deeper insights, accelerate research and ultimately, bring new therapies to patients faster."

To learn more, visit Mayo Clinic Platform_Orchestrate.

###

About Mayo Clinic Platform
Founded on Mayo Clinic's dedication to patient-centered care, Mayo Clinic Platform enables new knowledge, new solutions and new technologies through collaborations with health technology innovators to create a healthier world. To learn more, visit Mayo Clinic Platform.

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

Media contact:

• Caroline Auger, Mayo Clinic Platform Communications, newsbureau@mayo.edu

The post Mayo Clinic Platform_Orchestrate expands capabilities to accelerate cancer research and advance cancer care appeared first on Mayo Clinic News Network.